---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-045577"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:20:47.362720+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Carisma reports preliminary Phase 1 data for CT-0508; 40.7% target lesion reduction in monotherapy

## Summary
- In 14 monotherapy patients, 40.7% of target lesions reduced in size on ≥1 scan across all anatomic sites.
- Combination sub-study of CT-0508 with pembrolizumab enrolled 6 patients; data from first 3 shown.
- First two combination patients received corticosteroids prior to pembro; both had progressive disease as best response.
- Third combination patient achieved stable disease with 46% reduction in one target lesion; PD due to new brain met.
- Company notes corticosteroids may reverse CT-0508 activity based on in vitro cell death data.

## SEC filing metadata
- accession: 0001104659-24-045577
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465924045577/0001104659-24-045577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465924045577/tm2411506d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-045577
- JSON: https://secwatch.observer/filing/0001104659-24-045577.json
- Plain text: https://secwatch.observer/filing/0001104659-24-045577.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.